BridgeBio Pharma, Inc. To Host Investor Call To Discuss Phase 2 Data For Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)

Friday, March 11, 2022 1 min read

Key Takeaway: BridgeBio Pharma, Inc. To Host Investor Call To Discuss Phase 2 Data For Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)

Full Press Release Details

BridgeBio Pharma, Inc. To Host Investor Call To Discuss Phase 2 Data For Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I).